Stocks · News reference
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket
Avalon Holdings (NYSE:AWX) shares rose 10.5% in pre-market trading after posting strong Q2 earnings of 23 cents per share and sales of $20.898 million. Other stocks gaining pre-market include DarkIris Inc (NASDAQ:DKI), Jin Medical International Ltd (NASDAQ:ZJYL), and Volato Group Inc (NYSE:SOAR).
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 8:59 AM
- Checked
- Aug 10, 2026, 8:59 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Barnes & Noble, Carter's, Kohl's Join DoorDash Marketplace
Between new class schedules, sports practices, and the scramble to find the right size backpack and outfits, back-to-school season is one of the busiest shopping moments of the year and one of the most time-consuming.
Read original at benzinga12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
Gainers Fossil Group (NASDAQ:FOSL) stock rose 11.9% to $5.9 during Wednesday's after-market session. The market value of their outstanding shares is at $309.6 million. As per the press release, Q2 earnings came out
Read original at benzingaAirsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Read original at benzingaCreative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.
Read original at benzingaCreative Medical Technology Says All Patients Enrolled And Treated Across ADAPT Trial Of Olastrocel In Chronic Lower Back Pain, Including FDA-Cleared Opioid Expansion Cohort; Trial Moves To Follow-Up And Phase 3 Planning
Read original at benzinga